Results 81 to 90 of about 27,184 (256)

Comparative Risk of Hepatitis B Virus Reactivation in Patients Receiving Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitors for Liver Cancer

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 3, Page 383-395, February 2026.
In a cohort of 1596 liver cancer patients with either current or prior HBV infection undergoing systemic therapy in Hong Kong, the risk of HBV reactivation during immune checkpoint inhibitor treatment was low when adequate antiviral prophylaxis was administered, irrespective of HBV infection status.
Dorothy Cheuk‐Yan Yiu, Jimmy Che‐To Lai, Landon Long Chan, Grace Lai‐Hung Wong, Mandy Sze‐Man Lai, Vincent Wai‐Sun Wong, Yee‐Kit Tse, Henry Lik‐Yuen Chan, Stephen Lam Chan, Terry Cheuk‐Fung Yip   +9 more
wiley   +1 more source

Novel methods to estimate antiretroviral adherence: protocol for a longitudinal study. [PDF]

, 2018
BackgroundThere is currently no gold standard for assessing antiretroviral (ARV) adherence, so researchers often resort to the most feasible and cost-effective methods possible (eg, self-report), which may be biased or inaccurate.
Gandhi, Monica, Johnson, Mallory O, Legnitto, Dominique, Ming, Kristin, Neilands, Torsten B, Saberi, Parya   +5 more
core   +1 more source

Eight‐year efficacy and safety of tenofovir alafenamide for treatment of chronic hepatitis B virus infection: Final results from two randomised phase 3 trials

Alimentary Pharmacology and Therapeutics
In two phase 3 studies, tenofovir alafenamide (TAF) showed non‐inferior efficacy versus tenofovir disoproxil fumarate (TDF), with more favourable renal and bone safety in patients with chronic hepatitis B (CHB).
María Buti, Young-Suk Lim, H. Chan, Kosh Agarwal, Patrick Marcellin, M. Brunetto, Wan-Long Chuang, H.L. Janssen, Scott Fung, Namiki Izumi, Maciej S. Jablkowski, D. Abdurakhmanov, F. Abramov, Hongyuan Wang, Irina Botros, Leland J. Yee, Roberto Mateo, J. Flaherty, Anu Osinusi, Calvin Q. Pan, X. Shalimar, W. Seto, Edward J. Gane   +22 more
semanticscholar   +1 more source

Cryoglobulinemia: An update on classification, pathophysiology, clinical presentation, and management

Journal of Internal Medicine, Volume 299, Issue 2, Page 196-215, February 2026.
Abstract Cryoglobulinemia (CG) is defined by the presence of serum immunoglobulins that precipitate below 37°C and redissolve upon rewarming. It is classified into three types based on immunoglobulin composition. Type I, a rare form, involves monoclonal IgM or IgG and is linked to lymphoproliferative disorders.
Anna Linda Zignego, Laura Gragnani, Marcella Visentini, Riccardo Bomben, Luca Arcaini, Clodoveo Ferri, Valter Gattei, Cesare Mazzaro   +7 more
wiley   +1 more source

Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate for Preventing Vertical Transmission in Chronic Hepatitis B Mothers: A Systematic Review and Meta-Analysis

Clinical Infectious Diseases
Objective International guidelines recommend maternal tenofovir disoproxil fumarate (TDF) therapy accompanied by infant immunoprophylaxis to prevent hepatitis B virus (HBV) mother-to-child transmission (MTCT) in highly viremic mothers.
Calvin Q. Pan, Lin Zhu, Andy S Yu, Yuchan Zhao, Bo Zhu, Erhei Dai   +5 more
semanticscholar   +1 more source

Cost‐effectiveness of leveraging long‐acting injectable cabotegravir to expand PrEP coverage among MSM in two contrasting North American cities

Journal of the International AIDS Society, Volume 29, Issue 1, January 2026.
Abstract Introduction Long‐acting injectable cabotegravir (CAB‐LA) is superior to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for HIV pre‐exposure prophylaxis (PrEP) and could expand PrEP usage. Given price differentials between CAB‐LA and TDF/FTC, evaluating the cost‐effectiveness of potential PrEP coverage scenarios is warranted.
Jesse A. Heitner, Sarah E. Stansfield, Kate M. Mitchell, Carla M. Doyle, Rachael M. Milwid, Mia Moore, Deborah J. Donnell, Yiqing Xia, Mathieu Maheu‐Giroux, Ruanne V. Barnabas, Marie‐Claude Boily, Dobromir T. Dimitrov   +11 more
wiley   +1 more source

Profile of bictegravir/emtricitabine/tenofovir alafenamide fixed dose combination and its potential in the treatment of HIV-1 infection: evidence to date

HIV/AIDS: Research and Palliative Care, 2018
Lucas Hill,1 Shawn R Smith,1 Maile Young Karris2 1University of California San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, CA, USA; 2Department of Medicine, University of California San Diego, San Diego, CA, USA Abstract ...
Hill L, Smith SR, Karris MY
doaj  

Ending the HIV/AIDS epidemic in low- and middle-income countries by 2030: is it possible? [PDF]

, 2016
The international community has committed to ending the epidemics of HIV/AIDS, tuberculosis, malaria, and neglected tropical infections by 2030, and this bold stance deserves universal support.
Harries, Anthony D, Kyaw, Nang Thu Thu, Suthar, Amitabh B, Takarinda, Kudakwashe C, Tayler-Smith, Katie, Tweya, Hannock, Zachariah, Rony   +6 more
core   +2 more sources

Weight, Anthropometric and Metabolic Changes After Discontinuing Antiretroviral Therapy Containing Tenofovir Alafenamide in People With HIV

Clinical Infectious Diseases
Background Antiretroviral therapy (ART)-related weight gain is of particular concern in people with HIV (PWH). Although weight gain was observed among PWH receiving tenofovir alafenamide (TAF), little is known about the potential reversibility after TAF ...
J. Damas, Aline Munting, J. Fellay, D. Haerry, C. Marzolini, Philip E Tarr, Ana Steffen, Dominique L Braun, M. Stoeckle, E. Bernasconi, Olivier Nawej Tshikung, Christoph A Fux, K. Darling, C. Béguelin, G. Wandeler, M. Cavassini, B. Surial   +16 more
semanticscholar   +1 more source

Hepatitis B Virus Reactivation after Switch to Cabotegravir/Rilpivirine in Patient with Low Hepatitis B Surface Antibody

Emerging Infectious Diseases
A patient in Japan with HIV began antiretroviral therapy because of acute hepatitis B virus (HBV) 15 years ago, with low hepatitis B surface antibody, and experienced breakthrough HBV reactivation 4 months after switching from bictegravir/emtricitabine ...
Eisuke Adachi, Ayako Sedohara, Kotaro Arizono, Kazuaki Takahashi, Amato Otani, Yoshiaki Kanno, Makoto Saito, Michiko Koga, Hiroshi Yotsuyanagi   +8 more
doaj   +1 more source